Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis (Q82964583)
Jump to navigation
Jump to search
scientific article published on 14 December 2011
Language | Label | Description | Also known as |
---|---|---|---|
English | Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis |
scientific article published on 14 December 2011 |
Statements
Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis (English)
Sarah Krausz
Maria J H Boumans
Danielle M Gerlag
Joelle Lufkin
Arno W R van Kuijk
Alian Bakker
Maarten de Boer
Beatrijs M Lodde
Kris A Reedquist
Eric W Jacobson
Michael O'Meara
14 December 2011